Literature DB >> 30843070

Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016).

Helio S Sader1, Mariana Castanheira1, S J Ryan Arends1, Herman Goossens2, Robert K Flamm1.   

Abstract

BACKGROUND: The SENTRY Antimicrobial Surveillance Program monitors the frequency of occurrence and antimicrobial susceptibility of organisms from various infection types worldwide.
METHODS: A total of 102 995 bacterial isolates were consecutively collected (one per patient) in 1997-2016 from 258 medical centres in North America (n = 44 999; 113 centres), Europe (n = 30 988; 61 centres from 22 nations), the Asia-Pacific region (APAC; n = 16 503; 67 centres from 12 nations) and Latin America (n = 10 505; 17 centres from 7 nations). Organisms were isolated from respiratory tract specimens and tested for susceptibility by broth microdilution methods in a central laboratory.
RESULTS: Staphylococcus aureus (n = 24 351) and Pseudomonas aeruginosa (n = 22 279) were the most common organisms overall. Klebsiella spp. (n = 10 565) ranked third in North America, Europe and APAC. The proportion of Gram-negatives increased from 70.0%-74.7% to 80.9%-82.6% in Europe, APAC and Latin America, and remained stable (65.5%-66.1%) in North America. Methicillin resistance rates decreased substantially in all four regions from 2005-06 to 2015-16 among S. aureus isolates. P. aeruginosa susceptibility to meropenem decreased overall in the initial years, but increased in the last years of the investigation. Among Klebsiella spp. isolates, susceptibility to ceftriaxone/meropenem decreased from 85.9%/99.3% to 58.6%/85.8% in Europe and from 91.8%/99.5% to 81.6%/93.9% in APAC during the study period.
CONCLUSIONS: Rank order and susceptibility rates varied widely by geographical region and over time. The occurrence of some resistance phenotypes increased, though others decreased over the 20 years of the SENTRY Antimicrobial Surveillance Program.
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30843070     DOI: 10.1093/jac/dkz074

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  17 in total

1.  In Vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa.

Authors:  Tomefa E Asempa; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

Review 2.  Evasion of Antimicrobial Activity in Acinetobacter baumannii by Target Site Modifications: An Effective Resistance Mechanism.

Authors:  Arturo Martínez-Trejo; Juan Manuel Ruiz-Ruiz; Luis Uriel Gonzalez-Avila; Andrés Saldaña-Padilla; Cecilia Hernández-Cortez; Miguel Angel Loyola-Cruz; Juan Manuel Bello-López; Graciela Castro-Escarpulli
Journal:  Int J Mol Sci       Date:  2022-06-13       Impact factor: 6.208

3.  Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of Haemophilus influenzae from the United States and Europe.

Authors:  Helio S Sader; Cecilia G Carvalhaes; Leonard R Duncan; Dee Shortridge
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

4.  In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe.

Authors:  Cecilia G Carvalhaes; Leonard R Duncan; Wen Wang; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 5.  Rapid syndromic molecular testing in pneumonia: The current landscape and future potential.

Authors:  Stephen Poole; Tristan W Clark
Journal:  J Infect       Date:  2019-12-03       Impact factor: 6.072

Review 6.  The urgent need for metallo-β-lactamase inhibitors: an unattended global threat.

Authors:  Maria F Mojica; Maria-Agustina Rossi; Alejandro J Vila; Robert A Bonomo
Journal:  Lancet Infect Dis       Date:  2021-07-08       Impact factor: 25.071

Review 7.  Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia.

Authors:  Shampa Das; Diansong Zhou; Wright W Nichols; Andy Townsend; Paul Newell; Jianguo Li
Journal:  Eur J Clin Pharmacol       Date:  2019-12-14       Impact factor: 2.953

8.  Pathogenic characteristics of sputum and bronchoalveolar lavage fluid samples from patients with lower respiratory tract infection in a large teaching hospital in China: a retrospective study.

Authors:  Zheng Peng; Jin'an Zhou; Lei Tian
Journal:  BMC Pulm Med       Date:  2020-08-31       Impact factor: 3.317

9.  Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018.

Authors:  Cecilia G Carvalhaes; Dee Shortridge; Helio S Sader; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 10.  Pulmonary infections complicating ARDS.

Authors:  Charles-Edouard Luyt; Lila Bouadma; Andrew Conway Morris; Jayesh A Dhanani; Marin Kollef; Jeffrey Lipman; Ignacio Martin-Loeches; Saad Nseir; Otavio T Ranzani; Antoine Roquilly; Matthieu Schmidt; Antoni Torres; Jean-François Timsit
Journal:  Intensive Care Med       Date:  2020-11-11       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.